DOCSLIB.ORG

Srinivas Vinod Saladi Ph.D. Chabner Colloquium, 2019 Squamous Cell Carcinoma Genomic Landscape: Largely Tumor Suppressors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Srinivas Vinod Saladi Ph.D. Chabner Colloquium, 2019 Squamous Cell Carcinoma Genomic Landscape: Largely Tumor Suppressors Targeting SWI/SNF/Hippo pathway in Squamous Cancers Srinivas Vinod Saladi Ph.D. Chabner Colloquium, 2019 Squamous cell carcinoma genomic landscape: largely tumor suppressors Squamous NSCLC Hammerman et al, Nature, 2012 Head & Neck SCC Stransky et al, Science, 2011 Lung adenocarcinoma genotypes: many potential therapeutic opportunities AKT 1% ROS1 1.5% NRAS 1% BRAF 2% IDH1 <1% HER2 2% CTNNB1 2% ALK 3% PIK3CA 4% TP53 5% No Mutation ~40% EGFR 15% KRAS 23% Excision of p63 in SCC in vivo results in rapid tumor regression Oral SCC L/L p63 ; K14-CreER, Tamoxifen Controls CreER - Tamoxifen K14 +/+ +/+ p63 Day 0 Day 11 Tumor Volume CreER - K14 L/L L/L Days p63 Day 0 Day 13 100mg/kg tamoxifen daily days 1-5 p63 regulates genes by association with distinct epigenetic cofactors/complexes Cistrome analysis p63 ChIP-Seq (JHU029) Factors TP53 TCFP2L1 NRF1 TFCP2 SMARCC1 FOS E2F1 BCL11A FOSL2 (Ramsey, MR, He L, (Corrie LG, Ramsey SMARCA4 Forster N, et al, Cancer MR, et al, Genes & Dev, 2012) FOSL1 Research, 2011) BACH2 HDAC ACTL6A SMARCB1 RUVBL 1/2 p63 1/2 p63 TRIM28 H2AZ RUNX1 PUMA, NOXA SAMD9L p63 regulates genes by association with distinct epigenetic cofactors/complexes Cistrome analysis p63 ChIP-Seq (JHU029) Factors TP53 TCFP2L1 NRF1 TFCP2 SMARCC1 FOS E2F1 BCL11A Glycerol Gradient FOSL2 Smaller 440 kDa Larger SMARCA4 FOSL1 Empty 1 5 9 11 15 19 Input 7 13 17 21 3 BACH2 p63 SMARCB1 TRIM28 ACTL6A RUNX1 SWI/SNFBR-GATP1 –is dependentthe cent rchromatinal ATPas remodelinge in PBAF enzymes compl earexe highlys heterogeneous PBRM1 BRD7 P-BAF ARID2 BRG1 ATPase subunits PBAF-specific subunits BAF-specific subunits BRM SS18 Core subunits BRD9 ARID1A/ ARID1B BAF SWI/SNF complexes control nucleosome position DPF 1/2/3 BCL11 BRD9 A/B SS18 BAF BCL7 47 A/B/C ARID1A/ BRG1/ β-actin ARID1B BAF 60 BRM A/B/C SWI/SNF binding at BAF 53 SWI/SNF BAF specific loci BAF A/B BAF 57 170 155 ATP ADP BAF complexes Homo sapiens, Mus musculus PHF 10 BCL11 BRD7 A/B BAF BCL7 PBRM1 47 A/B/C β-actin ARID2 BAF 60 BRG1 A/B/C BAF 53 BAF Disruption of DNA-histone contacts BAF A/B BAF 57 170 155 Eviction Sliding PBAF complexes Homo sapiens, Mus musculus Core subunits BAF-specific subunits BAF & PBAF subunits PBAF-specific subunits SWI/SNF SWI/SNF complex mediated Transcriptional Regulation Kinetochore Transcriptional regulation Chromosome Chromatin (in highly condensed form) Anaphase Bridge Compact SWI/SNF Kinetochore è NO transcription factor accessibility Chromosome (ATP dependant) TF Open è Transcription factor accessibility Unwinding of Chromatin Proliferation Binding of Transcription Cell migration Factors Retinoblastoma pathway Immune response Transcription of Genes Embryonic stem cell and diffenciation programs Polycomb silencing Brownlee et al. DNA Repair 2015 Functions of SWI/SNF SWI/SNF enzymes play a key role in transcriptional regulation, replication, DNA repair, and cell cycle control. SWI/SNF enzymes are critical for cellular differentiation and embryonic development SWI/SNF subunits are mutated or deleted in many forms of cancer and one of the subunits BAF47 may act as tumor suppressor. Gastric carcinomas with lymph node metastasis over-express BRG1 and are depleted of BRM expression. BRG1 expression is high in invasive forms of prostate cancer. SWI/SNF complex altered in multiple cancers BAF/PBAF subunits mSWI/SNF complex (BAF) ARID1A PBRM1 Colorectal cancer SMARCA4 Leukemia-T-ALL Synovial sarcoma ARID2 ARID1B Leukemia/lymphoma Malignant SMARCA2 Myeloma rhabdoid tumors SMARCC2 Epithiloid sarcoma SMARCC1 Ovarian clear cell carcinoma SMARCB1 BRD7 Endometriod carcinoma Medulloblastoma ACTL6B Bladder cancer Breast cancer BCL11A Hepatocellular carcinoma Lung cancer BCL11B Neuroblastoma DPF2 Squamous cell carcinoma ACTL6A Small cell lung cancer Head and neck cancer SMARCD2 Clear cell BCL7C Pancreatic cancer meningioma SMARCD1 BRD9 PHF10 PHD3 Polybromo-containing BAF (PBAF) DPF3 SMARCE1 In-frame Head and neck Clear cell renal SMARCD3 Splice cancer carcinoma SS18L1 BCL7A Missense SS18 Truncating Hepatocellular DPF1 carcinoma BCL7B Head and neck 200 400 600 800 cancer Mutations in cBioPortal 1000 Kadoch et al. Human Cancer 2015 Kadoch et al. Biochemistry 2016 SWI/SNF complex widely considered as tumor suppressor Hodges & Crabtree, 2016 ACTL6A (Baf53a) subunit of SWI/SNF complex is amplified in multiple cancers Alteration Frequency Alteration ACTL6A (Baf53a) subunit of SWI/SNF complex is amplified in multiple cancers Immunodepletion ACTL6A SWI/SNF complex subunits complex SWI/SNF ARID1B ARID2 ACTL6B ACTL6A PBRM1 SMARCA2 BCL11b SMARCE1 ACTL6A (Baf53a): Progenitor State SMARCC1 ACTL6B (Baf53b): Differentiated State β-Tubulin (Saladi SV, et al, Epigenetics, 2011) ACTL6A is required for maintaining the progenitor state in epithelium (Bao X et al., Cell Stem Cell ,2013) ACTL6A is co-amplified with p63 and confers poor prognosis in HNSCC 3q26 TP63 ACTL6A Genetic Alteration (n=530) P63 ACTL6A Epidermis HNSCC ACTL6A is co-amplified with p63 and confers poor prognosis in HNSCC 3q26 TP63 ACTL6A Genetic Alteration (n=530) TCGA HNSCC Kaplan-Meier Survival for P63 ACTL6A ACTL6A Expression Epidermis HNSCC ACTL6A is required for tumor progression in vivo x" x" Harvest -Dox Tumors x" x" Harvest FaDu +Dox Tumors Dox inducible Inject Tumors (Day 8) (Day 20) shACTL6A Cells (Day 0) **** *** 202000 ) ) 3 3 m 1500 m 15 ( e m u l 101000 o V r o (X100mm 500 m 5 u Tumor Volume Tumor T 00 - Dox + Dox shACTL6A #1 #1 #2 Dox - + + ACTL6A is required for tumor progression in vivo - Dox + Dox x" x" Harvest -Dox Tumors x" x" Harvest Ki67 FaDu +Dox Tumors Dox inducible Inject Tumors (Day 8) (Day 20) shACTL6A Cells (Day 0) 6 **** Control *** shp63 202000 4 ) ) 3 3 K13 m 1500 m 15 ( 2 e m u l 101000 o V 0 r o (X100mm 500 m 5 50 u Tumor Volume Tumor 80 50 T 80 **** 80 ** 00 4040 - Dox + Dox shACTL6A 6060 #1 #1 #2 3030 Dox - + + 60 4040 2020 40 2020 1010 % K13 positive K13 % % Ki67 positive Ki67 % 20 00 00 Dox - Dox - + + 0 ACTL6A promotes transformation of mouse keratinocytes via activation of YAP Ras ) 150 RasRas + Vector (N=21) 150 3 Ras+p63 RasRaRas++ A+pCT 6ΔNp63αL36A (N=7) RasRas+ +A CTACTL6AL6A (N=7) 100 Ras+ACTL6A+p63 **** 100 50 *** Tumor Volume (mm Volume Tumor 0 8 10 14 17 20 22 25 27 29 32 36 38 40 42 44 47 49 51 Days 50 0 8 10 14 17 20 22 25 27 29 32 36 38 40 42 44 47 49 51 80 60 40 20 0 ACTL6A promotes transformation of mouse keratinocytes via activation of YAP Ras ) 150 RasRas + Vector (N=21) 150 3 Ras+p63 RasRaRas++ A+pCT 6ΔNp63αL36A (N=7) RasRas+ +A CTACTL6AL6A (N=7) 100 Ras+ACTL6A+p63 **** 100 50 *** Tumor Volume (mm Volume Tumor 0 8 10 14 17 20 22 25 27 29 32 36 38 40 42 44 47 49 51 Days 50 H&E DAPI Total-YAP Merged ACTL6A 0 ACTL6A 8 10 14 17 20 22 25 27 29 32 36 38 40 42 44 47 49 51 80 60 40 YAP1 20 p63 0 ACTL6A promotes Tumorigenesis in HNSCC P Cytoplasmic YAP1 retention Cytoplasm Regenerative YAP1 Proliferation SWI/SNF WWC11 ACTL6A p63 GPRC5A (?) Differentiation Nucleus Cancer Cell, 2017 ACTL6A inhibits SMARCA4 (BRG1) and correlates to high H3K27me3 (EZH2) at its target genes SWI/SNF antagonistic to PRC2 complex MCB, 2008 ARID1B is a specific vulnerability in ARID1A-mutant cancers. Helming KC, Wang X, Wilson BG, Vazquez F, Haswell JR, Manchester HE, Kim Y, Kryukov GV, Ghandi M, Aguirre AJ, Jagani Z, Wang Z, Garraway LA, Hahn WC, Roberts CW. Nat Med. 2014 Mar;20(3):251-4. doi: 10.1038/nm.3480. Epub 2014 Feb 23. SWI/SNF antagonizes PRC2 complex cSCC Kia SK,et al, Mol Cell Bio, 2008 Wilson B, et al, Cancer Cell, 2010 Saladi SV, et al, Pigment Cell & Mel Res, 2013 Poly Comb Repressor (PRC) complex Herviou et al. Oncotarget - 2016 SWI/SNF complex subunits alterations renders cells sensitive to EZH2 inhibitors ACTL6A ACTL6A expression correlates strongly with EZH2 expression 5,000 Pearson: 0.35 ACTL6A mutated Spearman: 0.38 EZH2 mutated Neither mutated 4,500 4,000 ) M E 3,500 S R 2 V q e 3,000 S A N R ( 2,500 n o i s s e r 2,000 p EZH2 x e A N R 1,500 m , 2 H Z E 1,000 500 0 0 1,000 2,000 3,000 4,000 5,000 6,000 7,000 ACTL6A, mRNA expression (RNA Seq V2 RSEM) ACTL6A EZH2 in HNSCC patients PDX (frozen) HNSCC (FFPE) EZH2 EZH2 Scale bar represents 50μM (PDX samples from Sara Pai) ACTL6A cooperates with EZH2 to repress differentiation programs Data 3 EZH2 0.20 0.20 IgG EZH2 0.15 0.15 IgG * * 0.10 0.10 * 0.05Input% of 0.05 0.00 0.00 1 9 4 C A F 0 L W 0 1 K W S WWC1 WWC1 ControlS100A9 S100A9 Control 55 5 5 shACTL6A shACTL6A Control WWC1 ControlControl 4 4 4 4 shACTL6A shACTL6AshACTL6A 5 33 3 3 4 22 2 2 3 % of Input% of % of Input% of * 11 1 1 * 2 * 00 * 0 0 1 A 7 3 G 60 2 H g A e 3 G L K I 6 M H g T 3 L 7 I C H T 2 A A 7 3 G C K 6 2 H g A 3 L K I H T 3 C H A ACTL6A cooperates with EZH2 and promotes H3K27me3 globally ACTL6A loci Global Control shACTL6A Control shACTL6A 6 4 2 (normalized input) to (normalized 0 -2 H3K27me3 log2 counts in 10Kb windows in H3K27me3 10Kb log2 windows counts SWI/SNF complex subunits alterations renders cells sensitive to EZH2 inhibitors EZH2 regulates differentiation program in SCC FaDu UT 6 100nM * 500nM 125 FaDu 125 125 Cal33 4 SCC4 100100 SCC4 * 100 HaCaTHaCaT * 75 2 * y 75 t i l i 50 b 75 50 a 0 i Relative mRNA levels Relative % Viable Cells 2525 A 1 V 5 C C 50 R W W % 0 0 P 0 0 1 1 102 1003 10004 100005 G FaDu 25 Log nM Tazemetostat 60 UT 100nM 0 HaCaT to FaDu:p= 0.043 * 500nM 0 1 2 HaCaT to3 SCC4: p=0.0134 40 * Conc (Log10 Scale) * 20 * * * 0 Relative mRNA levels Relative L 0 9 V 1 A I K 0 0 1 S One way ANOVA, multiple comparisions High mutation load in HNSCC Lawrence M, et al Nature, 2013 ACTL6A correlates to high mutation load in HNSCC 800 Rho = 0.64 700 p =
Load more

Recommended publications
  • ACTL6A Promotes the Proliferation of Esophageal Squamous Cell Carcinoma Cells and Correlates with Poor Clinical Outcomes
    OncoTargets and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH ACTL6A Promotes the Proliferation of Esophageal Squamous Cell Carcinoma Cells and Correlates with Poor Clinical Outcomes This article was published in the following Dove Press journal: OncoTargets and Therapy Rui-zhe Li1 Background: ACTL6A, a regulatory subunit of ATP-dependent chromatin-remodeling Yun-yun Li1,2 complexes SWI/SNF, has been identified as a central oncogenic driver in many tumor types. Hui Qin1 Materials and Methods: We used immunohistochemistry (IHC) to detect ACTL6A Shan-shan Li1 expression in esophageal squamous cell carcinoma (ESCC) tissues. Then, the effect of ACTL6A on proliferation and DNA synthesis was explored by using cell counting kit 8 1 Department of Pathology, School of (CCK8) and EdU retention assays. The potential oncogenic mechanism of ACTL6A in Basic Medical Sciences, Zhengzhou University and First Affiliated Hospital of ESCC cells was also analyzed by flow cytometry and Western blotting. We further estab­ Zhengzhou University, Zhengzhou, lished an ESCC xenograft mouse model to validate the in vitro results. Henan 450000, People’s Republic of China; 2Department of Stomatology, First Results: ACTL6A expression, localized in cancer cell nuclei, was markedly higher in ESCC Affiliated Hospital of Zhengzhou tissues than in the corresponding noncancerous tissues (P<0.001) and was positively asso­ University, Zhengzhou, Henan 450000, ciated with tumor size, histological differentiation, T stage and tumor-node-metastasis People’s Republic of China (TNM) stage. Kaplan–Meier analysis revealed that high ACTL6A expression was signifi­ cantly associated with poor overall survival (OS) (P = 0.008, HR= 2.562, 95% CI: 1.241–­ 5.289), and decision curve analysis (DCA) demonstrated that ACTL6A could increase the clinical prognostic efficiency of the original clinical prediction model.
    [Show full text]
  • Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade
    Published OnlineFirst May 4, 2017; DOI: 10.1158/2159-8290.CD-17-0292 RESEARCH ARTICLE Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade Yi-Feng Gu1,2, Shannon Cohn1,2, Alana Christie2, Tiffani McKenzie2,3, Nicholas Wolff1,2, Quyen N. Do4, Ananth J. Madhuranthakam4, Ivan Pedrosa2,4, Tao Wang2,5, Anwesha Dey6, Meinrad Busslinger7, Xian-Jin Xie2,8, Robert E. Hammer9, Renée M. McKay1,2, Payal Kapur2,3, and James Brugarolas1,2 Downloaded from cancerdiscovery.aacrjournals.org on September 26, 2021. © 2017 American Association for Cancer Research. 17-CD-17-0292_p900-917.indd 900 7/20/17 10:05 AM Published OnlineFirst May 4, 2017; DOI: 10.1158/2159-8290.CD-17-0292 ABSTRACT Clear cell renal cell carcinoma (ccRCC) is characterized by BAP1 and PBRM1 muta- tions, which are associated with tumors of different grade and prognosis. However, whether BAP1 and PBRM1 loss causes ccRCC and determines tumor grade is unclear. We conditionally targeted Bap1 and Pbrm1 (with Vhl ) in the mouse using several Cre drivers. Sglt2 and Villin proximal convoluted tubule drivers failed to cause tumorigenesis, challenging the conventional notion of ccRCC origins. In contrast, targeting with PAX8, a transcription factor frequently overexpressed in ccRCC, led to ccRCC of different grades. Bap1 -defi cient tumors were of high grade and showed greater mTORC1 activation than Pbrm1 -defi cient tumors, which exhibited longer latency. Disrupting one allele of the mTORC1 negative regulator, Tsc1 , in Pbrm1 -defi cient kidneys triggered higher grade ccRCC. This study establishes Bap1 and Pbrm1 as lineage-specifi c drivers of ccRCC and histologic grade, implicates mTORC1 as a tumor grade rheostat, and suggests that ccRCCs arise from Bowman capsule cells.
    [Show full text]
  • Increased ACTL6A Occupancy Within Mswi/SNF Chromatin Remodelers
    bioRxiv preprint doi: https://doi.org/10.1101/2021.03.22.435873; this version posted March 22, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Increased ACTL6A Occupancy Within mSWI/SNF Chromatin Remodelers Drives Human Squamous Cell Carcinoma Chiung-Ying Chang1,2,7, Zohar Shipony3,7, Ann Kuo1,2, Kyle M. Loh4,5, William J. Greenleaf3,6, Gerald R. Crabtree1,2,5* 1Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, California 94305, USA. 2Department of Pathology, Stanford University School of Medicine, Stanford, California 94305, USA. 3Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA. 4Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California 94305, USA. 5Department of Developmental Biology, Stanford University School of Medicine, Stanford, California 94305, USA. 6Department of Applied Physics, Stanford University, Stanford, California 94305, USA. 7These authors contributed equally. *Corresponding author: Gerald R. Crabtree, [email protected] Summary Mammalian SWI/SNF (BAF) chromatin remodelers play dosage-sensitive roles in many human malignancies and neurologic disorders. The gene encoding the BAF subunit, ACTL6A, is amplified at an early stage in the development of squamous cell carcinomas (SCCs), but its oncogenic role remains unclear. Here we demonstrate that ACTL6A overexpression leads to its stoichiometric assembly into BAF complexes and drives its interaction and engagement with specific regulatory regions in the genome. In normal epithelial cells, ACTL6A was sub-stoichiometric to other BAF subunits. However, increased ACTL6A levels by ectopic expression or in SCC cells led to near-saturation of ACTL6A within BAF complexes.
    [Show full text]
  • 1 Canonical BAF Complex in Regulatory T Cells 2 3 Chin
    bioRxiv preprint doi: https://doi.org/10.1101/2020.02.26.964981; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 A genome-wide CRISPR screen reveals a role for the BRD9-containing non- 2 canonical BAF complex in regulatory T cells 3 4 Chin-San Loo1,3,#, Jovylyn Gatchalian2,#, Yuqiong Liang1, Mathias Leblanc1, Mingjun 5 Xie1, Josephine Ho2, Bhargav Venkatraghavan1, Diana C. Hargreaves2*, and Ye 6 Zheng1* 7 8 1. NOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for 9 Biological Studies 10 2. Molecular and Cellular Biology Laboratory, Salk Institute for Biological Studies 11 3. Division of Biological Sciences, University of California, San Diego 12 # Co-first authors 13 * Co-corresponding authors 14 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.02.26.964981; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 15 Summary 16 Regulatory T cells (Tregs) play a pivotal role in suppressing auto-reactive T cells 17 and maintaining immune homeostasis. Treg development and function are 18 dependent on the transcription factor Foxp3. Here we performed a genome-wide 19 CRISPR/Cas9 knockout screen to identify the regulators of Foxp3 in mouse 20 primary Tregs. The results showed that Foxp3 regulators are highly enriched in 21 genes encoding SWI/SNF and SAGA complex subunits. Among the three 22 SWI/SNF-related complexes, the non-canonical or ncBAF (also called GBAF or 23 BRD9-containing BAF) complex promoted the expression of Foxp3, whereas the 24 PBAF complex repressed its expression.
    [Show full text]
  • Swi/Snf Chromatin Remodeling/Tumor Suppressor Complex Establishes Nucleosome Occupancy at Target Promoters
    Swi/Snf chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promoters Michael Y. Tolstorukova,b,1,2, Courtney G. Sansamc,d,e,1, Ping Luc,d,e,1, Edward C. Koellhofferc,d,e, Katherine C. Helmingc,d,e, Burak H. Alvera, Erik J. Tillmanc,d,e, Julia A. Evansc,d,e, Boris G. Wilsonc,d,e, Peter J. Parka,b,3, and Charles W. M. Robertsc,d,e,3 aCenter for Biomedical Informatics, Harvard Medical School, Boston, MA 02115; bDivision of Genetics, Brigham and Women’s Hospital, Boston, MA 02115; cDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115; dDivision of Hematology/Oncology, Boston Children’s Hospital, Boston, MA 02115; and eDepartment of Pediatrics, Harvard Medical School, Boston, MA 02115 Edited by Mark Groudine, Fred Hutchinson Cancer Research Center, Seattle, WA, and approved May 2, 2013 (received for review February 6, 2013) Precise nucleosome-positioning patterns at promoters are thought Brg1 haploinsufficient mice are tumor prone, establishing these to be crucial for faithful transcriptional regulation. However, the subunits of the complex as bona fide tumor suppressors (1, 12–17). mechanisms by which these patterns are established, are dynam- It is noteworthy that recent exome sequencing of 35 human SNF5- ically maintained, and subsequently contribute to transcriptional deficient rhabdoid tumors identified a remarkably low rate of control are poorly understood. The switch/sucrose non-fermentable mutations, with loss of SNF5 being essentially the sole recurrent event (18). Indeed, in two of the cancers, there were no other chromatin remodeling complex, also known as the Brg1 associated fi factors complex, is a master developmental regulator and tumor identi ed mutations.
    [Show full text]
  • Expressed Gene Fusions As Frequent Drivers of Poor Outcomes in Hormone Receptor–Positive Breast Cancer
    Published OnlineFirst December 14, 2017; DOI: 10.1158/2159-8290.CD-17-0535 RESEARCH ARTICLE Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor–Positive Breast Cancer Karina J. Matissek1,2, Maristela L. Onozato3, Sheng Sun1,2, Zongli Zheng2,3,4, Andrew Schultz1, Jesse Lee3, Kristofer Patel1, Piiha-Lotta Jerevall2,3, Srinivas Vinod Saladi1,2, Allison Macleay3, Mehrad Tavallai1,2, Tanja Badovinac-Crnjevic5, Carlos Barrios6, Nuran Beşe7, Arlene Chan8, Yanin Chavarri-Guerra9, Marcio Debiasi6, Elif Demirdögen10, Ünal Egeli10, Sahsuvar Gökgöz10, Henry Gomez11, Pedro Liedke6, Ismet Tasdelen10, Sahsine Tolunay10, Gustavo Werutsky6, Jessica St. Louis1, Nora Horick12, Dianne M. Finkelstein2,12, Long Phi Le2,3, Aditya Bardia1,2, Paul E. Goss1,2, Dennis C. Sgroi2,3, A. John Iafrate2,3, and Leif W. Ellisen1,2 ABSTRACT We sought to uncover genetic drivers of hormone receptor–positive (HR+) breast cancer, using a targeted next-generation sequencing approach for detecting expressed gene rearrangements without prior knowledge of the fusion partners. We identified inter- genic fusions involving driver genes, including PIK3CA, AKT3, RAF1, and ESR1, in 14% (24/173) of unselected patients with advanced HR+ breast cancer. FISH confirmed the corresponding chromo- somal rearrangements in both primary and metastatic tumors. Expression of novel kinase fusions in nontransformed cells deregulates phosphoprotein signaling, cell proliferation, and survival in three- dimensional culture, whereas expression in HR+ breast cancer models modulates estrogen-dependent growth and confers hormonal therapy resistance in vitro and in vivo. Strikingly, shorter overall survival was observed in patients with rearrangement-positive versus rearrangement-negative tumors. Cor- respondingly, fusions were uncommon (<5%) among 300 patients presenting with primary HR+ breast cancer.
    [Show full text]
  • Inactivation of the PBRM1 Tumor Suppressor Gene Amplifies
    Inactivation of the PBRM1 tumor suppressor gene − − amplifies the HIF-response in VHL / clear cell renal carcinoma Wenhua Gaoa, Wei Lib,c, Tengfei Xiaoa,b,c, Xiaole Shirley Liub,c, and William G. Kaelin Jr.a,d,1 aDepartment of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115; bCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215; cDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, MA 02115; and dHoward Hughes Medical Institute, Chevy Chase, MD 20815 Contributed by William G. Kaelin, Jr., December 1, 2016 (sent for review October 31, 2016; reviewed by Charles W. M. Roberts and Ali Shilatifard) Most clear cell renal carcinomas (ccRCCs) are initiated by somatic monolayer culture and in soft agar (10). These effects were not, inactivation of the VHL tumor suppressor gene. The VHL gene prod- however, proven to be on-target, and were not interrogated in uct, pVHL, is the substrate recognition unit of an ubiquitin ligase vivo. As a step toward understanding the role of BAF180 in that targets the HIF transcription factor for proteasomal degrada- ccRCC, we asked whether BAF180 participates in the canonical tion; inappropriate expression of HIF target genes drives renal car- PBAF complex in ccRCC cell lines and whether loss of BAF180 cinogenesis. Loss of pVHL is not sufficient, however, to cause ccRCC. measurably alters ccRCC behavior in cell culture and in mice. Additional cooperating genetic events, including intragenic muta- tions and copy number alterations, are required.
    [Show full text]
  • Rats and Axolotls Share a Common Molecular Signature After Spinal Cord Injury Enriched in Collagen-1
    Rats and axolotls share a common molecular signature after spinal cord injury enriched in collagen-1 Athanasios Didangelos1, Katalin Bartus1, Jure Tica1, Bernd Roschitzki2, Elizabeth J. Bradbury1 1Wolfson CARD King’s College London, United Kingdom. 2Centre for functional Genomics, ETH Zurich, Switzerland. Running title: spinal cord injury in rats and axolotls Correspondence: A Didangelos: [email protected] SUPPLEMENTAL FIGURES AND LEGENDS Supplemental Fig. 1: Rat 7 days microarray differentially regulated transcripts. A-B: Protein-protein interaction networks of upregulated (A) and downregulated (B) transcripts identified by microarray gene expression profiling of rat SCI (4 sham versus 4 injured spinal cord samples) 7 days post-injury. Microarray expression data and experimental information is publicly available online (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE45006) and is also summarised in Supplemental Table 1. Protein-protein interaction networks were performed in StringDB using the full range of protein interaction scores (0.15 – 0.99) to capture maximum evidence of proteins’ interactions. Networks were then further analysed for betweeness centrality and gene ontology (GO) annotations (BinGO) in Cytoscape. Node colour indicates betweeness centrality while edge colour and thickness indicate interaction score based on predicted functional links between nodes (green: low values; red: high values). C-D: The top 10 upregulated (C) or downregulated (D) transcripts sorted by betweeness centrality score in protein-protein interaction networks shown in A & B. E-F: Biological process GO analysis was performed on networks of upregulated and downregulated genes using BinGO in Cytoscape. Graphs indicate the 20 most significant GO categories and the number of genes in each category.
    [Show full text]
  • Supp Table 6.Pdf
    Supplementary Table 6. Processes associated to the 2037 SCL candidate target genes ID Symbol Entrez Gene Name Process NM_178114 AMIGO2 adhesion molecule with Ig-like domain 2 adhesion NM_033474 ARVCF armadillo repeat gene deletes in velocardiofacial syndrome adhesion NM_027060 BTBD9 BTB (POZ) domain containing 9 adhesion NM_001039149 CD226 CD226 molecule adhesion NM_010581 CD47 CD47 molecule adhesion NM_023370 CDH23 cadherin-like 23 adhesion NM_207298 CERCAM cerebral endothelial cell adhesion molecule adhesion NM_021719 CLDN15 claudin 15 adhesion NM_009902 CLDN3 claudin 3 adhesion NM_008779 CNTN3 contactin 3 (plasmacytoma associated) adhesion NM_015734 COL5A1 collagen, type V, alpha 1 adhesion NM_007803 CTTN cortactin adhesion NM_009142 CX3CL1 chemokine (C-X3-C motif) ligand 1 adhesion NM_031174 DSCAM Down syndrome cell adhesion molecule adhesion NM_145158 EMILIN2 elastin microfibril interfacer 2 adhesion NM_001081286 FAT1 FAT tumor suppressor homolog 1 (Drosophila) adhesion NM_001080814 FAT3 FAT tumor suppressor homolog 3 (Drosophila) adhesion NM_153795 FERMT3 fermitin family homolog 3 (Drosophila) adhesion NM_010494 ICAM2 intercellular adhesion molecule 2 adhesion NM_023892 ICAM4 (includes EG:3386) intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)adhesion NM_001001979 MEGF10 multiple EGF-like-domains 10 adhesion NM_172522 MEGF11 multiple EGF-like-domains 11 adhesion NM_010739 MUC13 mucin 13, cell surface associated adhesion NM_013610 NINJ1 ninjurin 1 adhesion NM_016718 NINJ2 ninjurin 2 adhesion NM_172932 NLGN3 neuroligin
    [Show full text]
  • Supplementary Table 6. Summary of Mutation Frequency And
    Supplementary table 6. Summary of mutation frequency and significance per microsatellite and per gene in exome sequencing of 24 and MiSeq sequencing of 93 MSI CRCs Summary of mutation frequency and significance per gene in exome sequencing of 24 and MiSeq sequencing of 93 MSI CRCs Gene MiSeq_MutFreq MiSeq_MutFreqCI95High MiSeq_MutFreqCI95Low MiSeq_MutatedTumors MiSeq_NAF MiSeq_P MiSeq_Q WXS_MutFreq WXS_MutatedTumors WXS_P WXS_Q CASP5 0.989247312 1.006838564 0.97165606 92 0.666666667 1.70E-89 4.83E-88 0.791666667 19 2.12E-17 1.33E-14 TGFBR2 0.967741935 0.997877874 0.937605997 90 0.883484163 1.48E-96 6.99E-95 0.833333333 20 4.39E-19 4.13E-16 SLC9A8 0.935483871 0.977386193 0.893581549 87 0.655034325 1.70E-89 4.83E-88 0.458333333 11 5.71E-07 5.25E-05 MIS18BP1 0.913978495 0.961803749 0.86615324 85 0.488888889 7.02E-61 9.07E-60 0.708333333 17 1.51E-08 1.97E-06 ACVR2A 0.892473118 0.945310572 0.839635665 83 0.80625 4.77E-128 6.77E-126 1 24 5.63E-36 2.12E-32 CDH26 0.88172043 0.936801974 0.826638886 82 0.55 4.12E-79 7.31E-78 0.416666667 10 5.46E-06 0.000331959 TFAM 0.88172043 0.936801974 0.826638886 82 0.620192308 4.12E-79 7.31E-78 0.583333333 14 2.52E-10 4.75E-08 ATR 0.860215054 0.919360254 0.801069854 80 0.632996633 2.72E-75 4.30E-74 0.583333333 14 3.89E-09 5.86E-07 AASDH 0.838709677 0.901442635 0.77597672 78 0.832712022 1.27E-71 1.80E-70 0.416666667 10 5.46E-06 0.000331959 USF3 0.806451613 0.873837619 0.739065607 75 0.771428571 5.39E-50 4.25E-49 0.5 12 0.002548628 0.01890901 SLC35F5 0.76344086 0.83592506 0.69095666 71 0.607908352 8.90E-60 1.05E-58
    [Show full text]
  • Epidyne®-FRET for Nucleosome Remodeling Assays
    Nucleosome Remodeling Assay by EpiDyne®-FRET EpiDyne®-FRET allows unprecedented access to disease-relevant ATP-dependent chromatin remodeling complexes FIGURE 3 SMARCA 2 SMARCA 4 EpiDyne®-FRET nucleosomes (20 nM) were incubated with Figure 3A Figure 3B chromatin remodeling enzyme (Panel 3A, SMARCA2; panel 3B, SMARCA4) at the indicated concentration in 4.0 3.5 the presence of ATP (2 mM). 3.5 Upon ATP addition, reactions 3.0 were immediately read in 3.0 an Envision Multi-label plate 2.5 reader. Data are presented as 2.5 the mean of the Cy3-Cy5 ratio 2.0 (N=2). 2.0 1.5 Cy3/Cy5 Ratio Cy3/Cy5 1.5 Ratio Cy3/Cy5 1.0 1.0 0 1 2 3 4 5 6 7 8 9 10 0 10 20 30 40 Time, Min Time, Min nM Enzyme nM Enzyme 28 14 7 3.5 0.0 12.50 6.25 3.13 1.56 0 ORDERING INFO Chromatin Remodeling Substrate, Fluorescent Readout Enzymes EpiDyne®-FRET Nucleosome Remodeling Assay Substrate SMARCA2 Chromatin Remodeling Enzyme Catalog No. 16-4201 (Human BRM) Pack Size: 50 μg Catalog No. 15-1015 Pack Size: 100 remodeling rxns Chromatin Remodeling Substrates, Non-Fluorescent Readout SMARCA4 Chromatin Remodeling Enzyme (Human BRG1) ST601-GATC1 ST601-GATC1, 50-N-66, Biotinylated Catalog No. 15-1014 Cat. No. 16-4101 Cat. No.: 16-4114 Pack Size: 100 remodeling rxns Pack Size: 50 μg Pack Size: 50 μg ACF Chromatin Remodeling Enzyme Complex ST601-GATC1, Biotinylated ST601-GATC1,2, 50-N-66, Biotinylated Catalog No. 15-1013 Cat.
    [Show full text]
  • SNF5/INI1 Deficiency Redefines Chromatin Remodeling Complex Composition During Tumor Development
    Published OnlineFirst July 9, 2014; DOI: 10.1158/1541-7786.MCR-14-0005 Molecular Cancer Chromatin, Gene, and RNA Regulation Research SNF5/INI1 Deficiency Redefines Chromatin Remodeling Complex Composition during Tumor Development Darmood Wei1, Dennis Goldfarb2, Shujie Song3,4, Courtney Cannon4,5, Feng Yan4, Donastas Sakellariou- Thompson4, Michael Emanuele4,5, Michael B. Major4,6, Bernard E. Weissman4,7, and Yasumichi Kuwahara4,8 Abstract Malignant rhabdoid tumors (MRT), a pediatric cancer that most frequently appears in the kidney and brain, generally lack SNF5 (SMARCB1/INI1), a subunit of the SWI/SNF chromatin-remodeling complex. Recent studies have established that multiple SWI/SNF complexes exist due to the presence or absence of different complex members. Therefore, the effect of SNF5 loss upon SWI/SNF complex formation was investigated in human MRT cells. MRT cells and primary human tumors exhibited reduced levels of many complex proteins. Furthermore, reexpression of SNF5 increased SWI/SNF complex protein levels without concomitant increases in mRNA. Proteomic analysis, using mass spectrometry, of MRT cells before and after SNF5 reexpression indicated the recruitment of different components into the complex along with the expulsion of others. IP–Western blotting confirmed these results and demonstrated similar changes in other MRT cell lines. Finally, reduced expression of SNF5 in normal human fibroblasts led to altered levels of these same complex members. These data establish that SNF5 loss during MRT development alters the repertoire of available SWI/SNF complexes, generally disrupting those associated with cellular differentiation. These findings support a model where SNF5 inactivation blocks the conversion of growth-promoting SWI/SNF complexes to differentiation-inducing ones.
    [Show full text]